BPC-157

BPC-157 is a synthetic peptide made of 15 amino acids (sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val; molecular weight ~1419.6 g/mol). It is a partial fragment derived from a larger "Body Protection Compound" protein originally isolated from human gastric (stomach) juice in 1993. It has been studied in laboratory and animal models as a "cytoprotective" agent claimed to support healing of tissues such as tendon, ligament, muscle, bone, gut lining, and skin. It is not a naturally occurring free peptide in the body and is not an approved medicine anywhere.

Education only. This page summarises published research and regulatory status. It is not medical advice and gives no dosing, preparation or administration instructions; any decision about use belongs with an independent qualified professional.

Also known as: Body Protection Compound 157, Gastric pentadecapeptide BPC-157, BPC 157, PL 14736, Bepecin, PLD-116
Class: Synthetic gastric pentadecapeptide (15-amino-acid cytoprotective / pro-angiogenic peptide); partial sequence of the human gastric juice protein BPC

How does BPC-157 work?

The mechanism is not fully established, but preclinical studies propose several overlapping pathways. BPC-157 appears to promote angiogenesis (new blood-vessel formation) by acting on the VEGFR2 receptor and the Akt-eNOS nitric-oxide axis, and to engage ERK1/2 growth-signaling in endothelial and fibroblast cells. It is also reported to upregulate growth factors, stabilize neuromuscular junctions, dampen pro-inflammatory cytokines (TNF-alpha, IL-6, IFN-gamma), and raise cytoprotective factors such as heme oxygenase-1. Notably, despite a very short measured half-life, animal effects persist for weeks to months, leading authors to describe it as a possible "biological switch" that initiates self-sustaining repair programs rather than acting continuously.

What has BPC-157 been studied for?

Tendon and ligament healing (preclinical)
Muscle regeneration and myotendinous junction repair (preclinical)
Bone healing (preclinical)
Gastrointestinal / gut mucosa and ulcer protection (preclinical)
Wound and skin healing (preclinical)
Spinal cord and nerve injury recovery (animal models)
Knee osteoarthritis pain (small retrospective human case series)
Interstitial cystitis / bladder (small human pilot)

What does the evidence show?

Evidence is overwhelmingly preclinical. There is an extensive body of rodent (rat/mouse) and some dog studies showing consistent regenerative and cytoprotective effects across many tissues. Human data are extremely limited: a 2025 narrative review identified only about three published human reports total — a retrospective series of intra-articular knee injections (most patients reported pain relief, but with no control group), a bladder-injection pilot in roughly a dozen patients, and a pharmacokinetics study in just two healthy adults. Major caveats: tiny samples, no randomized controlled trials, no placebo/control groups, no long-term outcome data, and a notable concentration of research from a small number of affiliated investigators. Reviewers explicitly flag likely publication bias ("All the published studies report positive or beneficial effects ... suggesting a possible publication bias toward positive findings") and conclude BPC-157 "should be considered investigational" until well-designed human trials exist. No "guaranteed" benefit or cure claim is supported.

What is known about the safety of BPC-157?

No serious adverse effects were reported in the few small human studies, and one preclinical safety evaluation found no teratogenic, genotoxic, anaphylactic, or local toxic effects. However, human safety is essentially unstudied: USADA notes "no one knows if there is a safe dose, or if there is any way to use this compound safely." Theoretical risks discussed in the literature include pathologic angiogenesis that could in principle promote tumor growth (though some preclinical work suggests the opposite, i.e., inhibition of uncontrolled proliferation), effects on nitric-oxide and proline metabolism, and unknown long-term consequences. A large real-world risk is product-side: grey-market/"research only" BPC-157 is not quality-controlled and may be contaminated, mislabeled, under/over-dosed, or contain impurities — the FDA has specifically warned about safety risks and potential contamination. Long-term effects in humans are entirely unknown.

What is the legal status of BPC-157?

Not approved by the FDA (or any major regulatory authority) for human use; it cannot be legally prescribed as an approved drug or sold over the counter as a drug, food, or dietary supplement. It is on the U.S. Department of Defense Prohibited Dietary Supplement Ingredients list. WADA prohibits it at all times (in and out of competition) under category S0 (Non-Approved Substances), in effect since 2022; athletes have received multi-year bans for its use. It is treated as a prescription-only medicine in Australia and New Zealand despite no legitimate approved product existing. US compounding status, October 2026: on 15 April 2026 the FDA removed BPC-157 from Category 2 of its interim 503A bulk-substances list, where it had been listed over safety concerns, and on 23-24 July 2026 the FDA's Pharmacy Compounding Advisory Committee voted to recommend adding it to the 503A bulks list. The vote is a non-binding recommendation, not a drug approval, and does not by itself let pharmacies compound it. On 14 October 2026 the FDA sent an “Interim Access Policy for Compounding Using Certain Peptides” to the White House Office of Information and Regulatory Affairs for review; as of 21 October 2026 its text and scope were not public and it was not in effect.

What is the half-life of BPC-157?

Very short. Measured plasma half-life in rats is approximately 7.9–30 minutes, and a human study reported plasma levels returning to baseline within roughly 24 hours. Despite this rapid clearance, animal functional improvements have been observed persisting for weeks to as long as ~360 days after dosing, suggesting biological effects outlast measurable drug presence.

Sources

From the Peppies Peptide Intelligence Library: an educational summary of the published literature, not medical advice. No dosing, preparation or administration instructions are given on these pages. Last updated 2026-09-24. Corrections: support@peppies.eu.